Key result
Isoproterenol infusion nearly doubles peak diastolic coronary blood velocity in healthy humans.
Why the study?
Do systemic adrenergic agonist infusions alter coronary blood flow in healthy human volunteers?
Population
14 healthy volunteers (11 men, 3 women) without cardiovascular, pulmonary, renal, or endocrine disease.
Comparison
Intravenous infusion of isoproterenol… vs Pre-infusion resting baseline.
Design
Other
Follow-up
Acute (during infusion)
Authors
Loading...
Adrenergic stimulation augments coronary flow in healthy humans; confirms beta-receptor mediation and extends mechanistic models for diseased states.
Do systemic adrenergic agonist infusions alter coronary blood flow in healthy human volunteers?
Absolute Event Rate: 43.9% vs 22.6%
p-value: p=<0.05
In healthy humans, beta-adrenergic stimulation via isoproterenol, terbutaline, and epinephrine increases coronary blood flow, whereas alpha-adrenergic stimulation with phenylephrine does not significantly alter it.
Pelaez et al. (2016) studied Healthy volunteers (n=14). Adrenergic agonists (isoproterenol, terbutaline, epinephrine, phenylephrine) and isometric handgrip exercise vs. Resting baseline (within-subjects design) was evaluated on Peak diastolic coronary blood velocity (CBVpeak) in response to isoproterenol (p=<0.05). Isometric handgrip exercise and low-dose, steady-state infusions of isoproterenol, terbutaline, and epinephrine elicited significant increases in peak diastolic coronary blood velocity in healthy humans.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: